Journal
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
Volume -, Issue -, Pages -Publisher
XIA & HE PUBLISHING INC
DOI: 10.14218/JCTH.2022.00212
Keywords
-
Categories
Funding
- National Research Founda-tion of Korea (NRF) - Korea government (MSIT) [NRF-2020R1C1C1010722]
Ask authors/readers for more resources
We report a case of a patient with c-MET amplified hepato-cellular carcinoma (HCC) who had a dramatic response to cabozantinib despite being refractory to previous lines of systemic therapy, maintaining a partial response for over 9 months.
We report a case of a patient with c-MET amplified hepato-cellular carcinoma (HCC) who had a dramatic response to cabozantinib despite being refractory to four previous lines of systemic therapy. The patient had previously received re-gorafenib plus nivolumab as first-line treatment, lenvatinib as second-line, sorafenib as third-line, and ipilimumab plus nivolumab as fourth-line treatment in sequence. However, all regimens showed early progression within 2 months. The pa-tient's HCC was well-controlled, with a partial response (PR) of over 9 months after beginning cabozantinib treatment. Although there were mild adverse events such as diarrhea and elevated liver enzymes, they were tolerable. Next -gen-eration sequencing (NGS) of the patient's previous surgical specimen indicated amplification of c-MET genes. Although it is well known that cabozantinib has excellent effectiveness for inhibiting c-MET at the preclinical level, to the best of our knowledge this is the first case of dramatic response to cabozantinib in a patient with advanced HCC with c-MET am-plification.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available